

References

I-25

1. Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. *Kidney Res Clin Pract.* 2015;34:170-179.
2. Klein C, Brennan DC. HLA and ABO sensitization and desensitization in renal transplantation. UpToDate. Last updated January 23, 2015.
3. Krishnan NS, Zehnder D, Briggs D, Higgins R. Human leukocyte antigen antibody incompatible renal transplantation. *IJN.* 2014:409-414.
4. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. *Immunological Reviews.* 2014;258: 183–207.
5. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: overcoming the immunologic barriers to transplantation. *Journal of Immunology Research.* 2017; 2017:1-11.
6. Jordan SC, Lorant T, Choi J, Kjellman C. IgG endopeptidase in highly sensitized patients undergoing transplantation. *New England Journal of Medicine.* 2017;377:442-453.
7. Green H, Nesher E, Aizner S, et al. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients. *Clinical Transplantation.* 2019;33(6):1-13.
8. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Rituximab. 2020.
9. Micromedex®Solutions Compendia. 2020. Rituximab
10. Sasaki H, Hotta K, Mitsuke A, et al. Long-Term outcome of ABO-incompatible kidney transplantation in patients treated with low-dose rituximab regimen. *Transplant Proc.* 2021;53(3):989-994.